Bicarbonate may not benefit all patients with metabolic acidosis. After SODa-BIC, the question is no longer whether it works, but which patients, might still benefit.
Check out the VA by Daniel Ramirez #NephJC
Finerenone across the proteinuric CKD spectrum
Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
FIND CKD: The Visual Abstract
Is finerenone ready to move beyond diabetes?
The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD.
The next challenge is no longer whether finerenone belongs in non-diabetic CKD, but how to best combine with the rest of the pillars to maximize protection.
Check out the newest VA created by our intern Raquel Barba
FIND CKD: El Resumen Visual
¿Está la finerenona lista para ir más allá de la diabetes?
El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC no diabética.
El siguiente reto ya no es si la finerenona tiene un lugar en la ERC no diabética, sino cómo combinarla de la mejor manera con el resto de los pilares del tratamiento para maximizar la protección renal.
No se pierdan el nuevo Visual Abstract creado por nuestra interna Raquel Barba
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Track: The Visual Abstract
Can rivaroxaban reduce cardiovascular events in advanced CKD?
The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high cardiovascular risk.
Check out the latest VA and review the next #NephJC.
Track: El Resumen Visual
¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada?
El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en diálisis con alto riesgo cardiovascular.
Revisa nuestro más reciente resumen visual y acompáñanos en la próxima discusión de #NephJC.
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial)
Can we predict who benefits from steroids in IgAN? The PRED-IgAN Study
Majesty: The Visual Abstract
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy.
👑 Is deeper B-cell depletion enough to claim the throne?
📖 Check out the latest Visual Abstract by Dr Divya Bajpai
Majesty: El Resumen Visual
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa primaria.
👑 ¿Será suficiente una depleción más profunda de células B para reclamar el trono?
📖 Revisa el más reciente resumen visual elaborado por la Dra Divya Bajpai
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates
Is all kidney disease in Diabetics "Diabetic Nephropathy"?
Nefrópatia no diabética: El Resumen Visual
¿Hemos subestimado la frecuencia de la nefrópatía no diabética (NND) en pacientes diabeticos? Una cohorte basada en biopsias renales de 49,075 pacientes refuerza cuán heterogénea puede ser la NND y destaca las características clínicas más asociadas con la NND. ¿A quién debemos biopsiar? ¿Cuándo debemos sospecharla? ¿Cómo puede la histología cambiar el pronóstico?
Acompáñanos este martes en la discusión de #NephJC.
Nondiabetic Kidney Disease: The Visual Abstract
Have we been underestimating NDKD in patients with diabetes? A biopsy-based cohort of 49,075 patients reinforces just how heterogeneous kidney disease can be in DN and highlights the clinical features most strongly associated with NDKD. So, who should we biopsy? When should we suspect NDKD? And how can histology change prognosis?
Join us for this tuesday on the #NephJC discussion
NephJC Internship 2026-2027
Making an IMPACT on BP: Why pills alone won't win the war
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
IMPACTS-BP: The Visual Abstract
Can multifaceted strategies improve hypertension control in low-income patients?
Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood pressure control continues to be a major challenge, especially in low-income populations. The IMPACTS-BP trial has arrived, a study evaluating whether a multifaceted team-based strategy can improve blood pressure control and adherence to antihypertensive therapy.
Check out the VA by Dra Akshaya Jayachandran, and don’t forget to join the live discussion with @NephJC on X and Bluesky